Insights on Microsomal Prostaglandin E2 Synthase 1 (mPGES-1) Inhibitors using Molecular Dynamics and MM/PBSA Calculations

被引:3
作者
dos Santos Nascimento, Igor Jose [1 ,2 ,3 ]
de Aquino, Thiago Mendonca [4 ]
da Silva Junior, Edeildo Ferreira [4 ]
de Moura, Ricardo Olimpio [3 ]
机构
[1] Estacio Alagoas Coll, Pharm Dept, Maceio, Brazil
[2] Cesmac Univ Ctr, Pharm Dept, Maceio, Brazil
[3] State Univ Paraiba, Dept Pharm, Drug Dev & Synth Lab, BR-58429500 Campina Grande, Brazil
[4] Univ Fed Alagoas, Inst Chem & Biotechnol, Lab Synth & Res Med Chem, Maceio, Brazil
关键词
COX-2; inhibitors; mPGES-1; PGE(2); molecular dynamics; molecular docking; MM-PBSA calculations; RMSD; GENETIC DELETION; DUAL INHIBITORS; DRUG DESIGN; DERIVATIVES; DOCKING; 5-LIPOXYGENASE; INFLAMMATION; DISCOVERY; GROMACS; BINDING;
D O I
10.2174/1570180820666230228105833
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: Despite being a normal body response against invading agents, inflammation, when exaggerated, needs to be controlled to minimize damage to the body. There are several drugs in clinical use against inflammation and other inflammatory conditions. Still, side effects often limit the use of these drugs, such as gastrointestinal effects generated by COX-1 inhibitors and cardiovascular effects by COX-2 inhibitors. Thus, exploring new targets such as mPGES-1 may lead to discovering agents that are more selective against inflammation and generate fewer side effects. Objectives: Here, docking, molecular dynamics, and MM-PBSA studies were performed on a dataset of known mPGES-1 inhibitors to identify helpful information and discover new mPGES-1 inhibitors. Methods: Molecular docking in GOLD software was used to obtain the complexes used in Molecular dynamics simulations (GROMACS software), performed to generate the RMSD, RMSF, R-g, SASA, and H-bond plots to predict the complexes' stability. The most stable conformation was analyzed regarding the most important interactions of the compounds. Finally, MM-PBSA calculations using the tool g_mmpbsa in GROMACS software were performed to determine de-binding affinity, interaction parameters, and per-residue contribution. Results: The main findings of this work were that the molecular dynamics simulation was able to find the open conformation of mPGES-1, which showed a greater preference on compounds in this region, consisting of residues known as "gateways". All compounds showed stability and stable complex formation with mPGES-1, as demonstrated by the results of RMSD, RMSF, R-g, SASA, and H-bond plots generated in a molecular dynamics simulation at 100 ns. The molecular dynamics identified three preferential sites of interaction for the compounds. Thus, the docking and dynamics protocols showed greater affinity of these compounds for cavity-02, interacting with Leu(85), Pro(81), Gln(134), Cys(137), Ala(138), and Ala(141). On the other hand, compound 09 preferred the cavity-03 of the protein, interacting mainly with His(72) through H-bond. In addition, MM-PBSA calculations showed binding energies of up to -220,113 KJ/mol for compound 04. Furthermore, MM-PBSA could identify which electrostatic interactions are the most prevalent in the complex formation of the compounds with the highest affinity (04 and 07). Still, the van der Waals interactions are the most important for the others. Finally, the energy contribution per-residue revealed Lys(120), Arg(122), Arg(126), and Tyr(130) as the most important for the formation of the complexes. Conclusion: Design mPGES-1 inhibitors based on the residues Leu(85), Pro(81), Gln(134), Cys(137), Ala(138), and Ala(141), in addition to Lys(120), Arg(122), Arg(126), and Tyr(130) can provide new promising drugs useful against diseases involving inflammatory conditions.
引用
收藏
页码:1033 / 1047
页数:15
相关论文
共 50 条
  • [21] Chemistry and biology of microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors as novel anti-inflammatory agents: recent developments and current status
    Khurana, Puneet
    Jachak, Sanjay M.
    RSC ADVANCES, 2016, 6 (34) : 28343 - 28369
  • [22] Upregulation of Cyclooxygenase-2 (COX-2) and Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) in Wall of Ruptured Human Cerebral Aneurysms Preliminary Results
    Hasan, David
    Hashimoto, Tomoki
    Kung, David
    Macdonald, R. Loch
    Winn, H. Richard
    Heistad, Donald
    STROKE, 2012, 43 (07) : 1964 - 1967
  • [23] Exploration of the dihydropyrimidine scaffold for the development of new potential anti-inflammatory agents blocking prostaglandin E2 synthase-1 enzyme (mPGES-1)
    Lauro, Gianluigi
    Strocchia, Maria
    Terracciano, Stefania
    Bruno, Ines
    Fischer, Katrin
    Pergola, Carlo
    Werz, Oliver
    Riccio, Raffaele
    Bifulco, Giuseppe
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 80 : 407 - 415
  • [24] In Silico Study on Flavonoids from Red Betel as Microsomal Prostaglandin E Synthase-1 (mPGES-1) Inhibitors in Rheumatoid Arthritis
    Afifah, Solichatul
    Amalia, Atikah
    Maslikah, Siti Imroatul
    INTERNATIONAL CONFERENCE ON BIOLOGY AND APPLIED SCIENCE (ICOBAS), 2019, 2120
  • [25] c-Fos immunoreactivity induced by intraperitoneal LPS administration is reduced in the brain of mice lacking the microsomal prostaglandin E synthase-1 (mPGES-1)
    Dallaporta, M.
    Pecchi, E.
    Jacques, C.
    Berenbaum, F.
    Jean, A.
    Thirion, S.
    Troadec, J. D.
    BRAIN BEHAVIOR AND IMMUNITY, 2007, 21 (08) : 1109 - 1121
  • [26] Tricyclic 4,4-dimethyl-3,4-dihydrochromeno[3,4-d]imidazole derivatives as microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors: SAR and in vivo efficacy in hyperalgesia pain model
    Muthukaman, Nagarajan
    Tambe, Macchindra
    Shaikh, Mahamadhanif
    Pisal, Dnyandeo
    Deshmukh, Sanjay
    Tondlekar, Shital
    Sarode, Neelam
    Narayana, Lakshminarayana
    Gajera, Jitendra M.
    Kattige, Vidya G.
    Honnegowda, Srinivasa
    Karande, Vikas
    Kulkarni, Abhay
    Behera, Dayanidhi
    Jadhav, Satyawan B.
    Gudi, Girish S.
    Khairatkar-Joshi, Neelima
    Gharat, Laxmikant A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2017, 27 (11) : 2594 - 2601
  • [27] Design and Development of Microsomal Prostaglandin E2 Synthase-1 Inhibitors: Challenges and Future Directions
    Koeberle, Andreas
    Laufer, Stefan A.
    Werz, Oliver
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (13) : 5970 - 5986
  • [28] Microsomal prostaglandin E synthase-1: the inducible synthase for prostaglandin E2
    Annaleise V Sampey
    Seetha Monrad
    Leslie J Crofford
    Arthritis Research & Therapy, 7
  • [29] The functional link between microsomal prostaglandin E synthase-1 (mPGES-1) and peroxisome proliferator-activated receptor γ (PPARγ) in the onset of inflammation
    Maione, Francesco
    Casillo, Gian Marco
    Raucci, Federica
    Iqbal, Asif J.
    Mascolo, Nicola
    PHARMACOLOGICAL RESEARCH, 2020, 157
  • [30] Microsomal Prostaglandin E2 Synthase-1 as a New Macromolecular Drug Target in the Prevention of Inflammation and Cancer
    Bulbul, Bahadir
    Kucukguzel, Ilkay
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2019, 19 (10) : 1205 - 1222